Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Verine, Jérôme ^a,b,c,d   Lehmann Che, Jacqueline ^c,d,e   Soliman, Hany ^d,e   Feugeas, Jean Paul ^c,d,e   Vidal, Jean Sébastien ^a   Mongiat Artus, Pierre ^c,d,e   Belhadj, Stéphanie ^a   Philippe, Josette ^a,b   Lesage, Matthieu ^a,b   Wittmer, Evelyne ^d   Chanel, Stéphane ^f   Couvelard, Anne ^g   Ferlicot, Sophie ^h   Rioux Leclercq, Nathalie ⁱ   Vignaud, Jean Michel ^j   Janin, Anne ^a,c,d   Germain, Stéphane ^a,b  

^a INSERM   (France)

^b l'alimentation et l'Environnement   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e Institut Universitaire d'Hématologie   (France)

^f LABORATOIRE CERBA   (France)

^g BEAUJON HOSPITAL   (France)

^h BICÊTRE HOSPITAL   (France)

ⁱ RENNES UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; ANGPTL4 PROTEIN, HUMAN; BIOLOGICAL MARKER; MESSENGER RNA; RNA;

ARTICLE; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION; GENE INACTIVATION; HEMANGIOBLASTOMA; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; METASTASIS; ONCOCYTOMA; OVERALL SURVIVAL; PANCREAS TUMOR; PAPILLARY CARCINOMA; PHEOCHROMOCYTOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; TUMOR VOLUME; DIFFERENTIAL DIAGNOSIS; GENETICS; IN SITU HYBRIDIZATION; MOLECULAR DIAGNOSIS; PATHOLOGY; RETROSPECTIVE STUDY;

ANGIOPOIETINS; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; IN SITU HYBRIDIZATION; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; RNA, MESSENGER; RNA, NEOPLASM;

EID: 77956411514     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010421     Document Type: Article

References (33)

1. Pascual D, Borque A (2008) Epidemiology of kidney cancer. Adv Urol: 782381.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592.
3. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353: 2477-2490.
4. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373: 1119-1132.
5. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, et al. (2009) 2009 update on the classification of renal epithelial tumors in adults. Int J Urol 16: 432-443.
6. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, et al. (2008) Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14: 4726-4734.
7. Nyhan MJ, O'Sullivan GC, McKenna SL (2008) Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans 36: 472-478.
8. Kaelin WG (2007) Von Hippel-Lindau disease. Annu Rev Pathol 2: 145-173.
9. Kaelin WG, Jr. (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
10. Osunkoya AO, Yin-Goen Q, Phan JH, Moffitt RA, Stokes TH, et al. (2009) Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis. Hum Pathol.
11. Ortiz-Rey JA, Gomez De Maria C, Pelaez Boismorand E, Fernandez Costas A, Barbosa Barreiro MJ, et al. (2006) [Expression of CD10 and renal cell carcinoma marker in clear cell renal cell carcinoma: analysis on tissue arrays]. Actas Urol Esp 30: 281-286.
12. Gupta R, Balzer B, Picken M, Osunkoya AO, Shet T, et al. (2009) Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol 33: 241-247.
13. Pan CC, Chen PC, Ho DM (2004) The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology 45: 452-459.
14. Skinnider BF, Amin MB (2005) An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol 22: 51-68.
15. Allory Y, Bazille C, Vieillefond A, Molinie V, Cochand-Priollet B, et al. (2008) Profiling and classification tree applied to renal epithelial tumours. Histopathology 52: 158-166.
16. Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, et al. (2006) Angiopoietin- like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci U S A 103: 18721-18726.
17. Chomel C, Cazes A, Faye C, Bignon M, Gomez E, et al. (2009) Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. Faseb J 23: 940-949.
18. Yau MH, Wang Y, Lam KS, Zhang J, Wu D, et al. (2009) A highly conserved motif within the NH2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization. J Biol Chem 284: 11942-11952.
19. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, et al. (2008) TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133: 66-77.
20. Le Jan S, Amy C, Cazes A, Monnot C, Lamande N, et al. (2003) Angiopoietin- like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 162: 1521-1528.
21. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663.
22. Ficarra V, Galfano A, Mancini M, Martignoni G, Artibani W (2007) TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol 8: 554-558.
23. Weinbreck N, Marie B, Bressenot A, Montagne K, Joud A, et al. (2008) Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining. Am J Surg Pathol 32: 1051-1059.
24. Perigny M, Hammel P, Corcos O, Larochelle O, Giraud S, et al. (2009) Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression. Am J Surg Pathol 33: 739-748.
25. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, et al. (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10: 764-771.
26. Gokden N, Gokden M, Phan DC, McKenney JK (2008) The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol 32: 1462-1467.
27. Hu Z, Fan C, Livasy C, He X, Oh DS, et al. (2009) A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 7: 9.
28. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, et al. (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 98: 9754-9759.
29. Lane BR, Li J, Zhou M, Babineau D, Faber P, et al. (2009) Differential expression in clear cell renal cell carcinoma identified by gene expression profiling. J Urol 181: 849-860.
30. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, et al. (2006) Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 3: e13.
31. Wuttig D, Baier B, Fuessel S, Meinhardt M, Herr A, et al. (2009) Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer 125: 474-482.
32. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90.
33. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, et al. (2002) VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 196: 186-193.